Twinbeech Capital LP Aurinia Pharmaceuticals Inc. Transaction History

Twinbeech Capital LP

  • $4.91 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$7.13 - $9.49 $963,519 - $1.28 Million
-135,136 Reduced 92.98%
10,209 $91,000
Q3 2023

Nov 14, 2023
BUY
$7.77 - $12.27 $1.13 Million - $1.78 Million
145,345 New
145,345 $1.13 Million
Q2 2022

Aug 15, 2022
BUY
$8.95 - $12.8 $580,971 - $830,886
64,913 New
64,913 $652,000
Q1 2022

May 16, 2022
SELL
$10.05 - $22.48 $377,287 - $843,921
-37,541 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$17.78 - $33.08 $667,478 - $1.24 Million
37,541 New
37,541 $859,000

Others Institutions Holding AUPH

# of Institutions
191
Shares Held
56.2M
Call Options Held
499K
Put Options Held
637K
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.03B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email